3 completed, 2 terminated, 1 approved for marketing. 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow uridine triacetate: new trials by email Literature Review of uridine triacetate trials Research Report on uridine triacetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria uridine triacetate - Hereditary Orotic Aciduria | Phase 3 | Completed | Wellstat Therapeutics | 4 | 2014-04-01 | 2017-07-31 |
| Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors triacetyluridine, fluorouracil, leucovorin - Solid Tumors | Phase 1 | Terminated | Wellstat Therapeutics | 24 | 2002-08-01 | 2005-06-24 |
| Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer fluorouracil, gemcitabine hydrochloride, triacetyluridine - Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer | Phase 3 | Completed | Wellstat Therapeutics | 250 | 2001-02-01 | 2012-06-28 |
| S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach fluorouracil, leucovorin calcium, triacetyluridine - Esophageal Cancer, Gastric Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 65 | 2001-02-01 | 2011-07-25 |
| RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease RG2133 (2',3',5'-tri-O-acetyluridine) - Mitochondrial Diseases | Phase 1 | Terminated | Repligen Corporation | 12 | 2005-08-05 | |
| Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination uridine triacetate - Toxicity Due to Chemotherapy | Approved for marketing | Wellstat Therapeutics | 2016-03-07 |
Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Esophageal Neoplasms (1) · Mitochondrial Diseases (1) · Oroticaciduria 1 (1) · Pancreatic Neoplasms (1)
Wellstat Therapeutics (4) · Repligen Corporation (1) · SWOG Cancer Research Network (1)
United States (4) · Canada (1)
James H. Doroshow, MD (1) · Lenny Smith, MS (1) · Michael K. Bamat, Ph.D. (1)